Literature DB >> 8853678

Structure and practice of institutional review boards in the United States.

J S Jones1, L J White, L C Pool, J M Dougherty.   

Abstract

OBJECTIVE: The institutional review board (IRB) is a critical element in the protection of patients' and subjects' rights with regard to their participation in research protocols. The purpose of this study was to describe the structure and current practices of IRBs in the United States.
METHODS: A self-administered questionnaire was mailed to the IRB chair of each U.S. hospital with a capacity of at least 400 beds (n = 907). The survey contained 21 questions outlining committee size and structure, review of research proposals, and policies concerning scientific misconduct. Chairs also were asked what advice they would offer a young investigator preparing a proposal for submission.
RESULTS: A total of 488 surveys (54%) were returned; 447 of the responding institutions had an IRB committee. Committees had an average of 14 members, representing 27 medical specialties. Orthopedics had the least IRB representation (10% of committees), followed by emergency medicine (12%) and ophthalmology (15%). The majority of research proposals go through 5 specific steps once submitted for review. Common reasons for proposal rejection were improperly designed consent form (54%), poor study design (44%), unacceptable risk to subjects (34%), ethical or legal reasons (24%), and scientific merit (14%). When a research proposal is rejected, 86% of the responding IRBs assist the investigator in making appropriate revisions. Although a number of IRBs (17%) have dealt with scientific misconduct allegations, only 58% have a written policy regarding research integrity.
CONCLUSION: Despite variations in committee structure and representation, IRBs have similar procedures for governing research. Investigators should be familiar with these procedures and are encouraged to discuss their proposal with an IRB representative prior to formal review.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Year:  1996        PMID: 8853678     DOI: 10.1111/j.1553-2712.1996.tb03519.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  9 in total

Review 1.  AOA Symposium. Barriers (threats) to clinical research.

Authors:  J L Marsh; William McMaster; Javad Parvizi; Stephen I Katz; Kurt Spindler
Journal:  J Bone Joint Surg Am       Date:  2008-08       Impact factor: 5.284

2.  Views and experiences of IRBs concerning research integrity.

Authors:  Robert Klitzman
Journal:  J Law Med Ethics       Date:  2011       Impact factor: 1.718

3.  Using the Emanuel et al. framework to assess ethical issues raised by a biomedical research ethics committee in South Africa.

Authors:  Joyce M Tsoka-Gwegweni; Douglas R Wassenaar
Journal:  J Empir Res Hum Res Ethics       Date:  2014-10-13       Impact factor: 1.742

Review 4.  A systematic review of the empirical literature evaluating IRBs: what we know and what we still need to learn.

Authors:  Lura Abbott; Christine Grady
Journal:  J Empir Res Hum Res Ethics       Date:  2011-03       Impact factor: 1.742

5.  Factors influencing the effectiveness of research ethics committees.

Authors:  C A Schuppli; D Fraser
Journal:  J Med Ethics       Date:  2007-05       Impact factor: 2.903

6.  Inclusion of women, minorities, and children in clinical trials: opinions of research ethics board administrators.

Authors:  Holly A Taylor
Journal:  J Empir Res Hum Res Ethics       Date:  2009-06       Impact factor: 1.742

7.  The investigator and the IRB: a survey of depression and schizophrenia researchers.

Authors:  Bernard A Fischer; Praveen George
Journal:  Schizophr Res       Date:  2010-01-12       Impact factor: 4.939

8.  Institutional review boards - a mixed blessing.

Authors:  Taimur Saleem; Umair Khalid
Journal:  Int Arch Med       Date:  2011-06-20

9.  Insights into the perception that research ethics committees are a barrier to research with seriously ill children: A study of committee minutes and correspondence with researchers studying seriously ill children.

Authors:  Ashleigh E Butler; Katherine Vincent; Myra Bluebond-Langner
Journal:  Palliat Med       Date:  2019-11-04       Impact factor: 4.762

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.